3 results
The first objective is to validate novel digital biomarkers for disease progression in de novo Parkinson*s disease patients. The biomarkers can eventually serve as a primary clinical endpoint in additional future clinical studies. As part of this…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatory eosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-head comparison of the presence…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…